Compare Adaptive Biotechnologies Corp (ADPT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Novo Nordisk A/S — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Novo Nordisk A/S trades at $48.92 (market cap $220.20B). The key difference: Novo Nordisk A/S is far larger — about 66.1× Adaptive Biotechnologies Corp's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NVO | |
|---|---|---|
Market Cap | $3.33B | $220.20B |
Sector | Health | Health |
52-Week High | $22.37 | $71.70 |
52-Week Low | $10.24 | $35.29 |
Enterprise Value | $3.19B | $239.16B |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
